Home   Case of Week Home   Jobs  Conferences   Fellowships   Books

Case of the Week #217

16 September 2011 Ė Case of the Week #217

This email is only sent to subscribers. To subscribe or unsubscribe to this or our other email lists, click here.

All cases are archived on our website. To view them sorted by number, diagnosis or category, visit our Home Page and click on the Case of the Week button on the left hand side.

Thanks to Dr. Hayam Abdel Samie Aiad, Menoufiya University, Egypt for contributing this case. To contribute a Case of the Week, follow the guidelines on our Case of the Week page.


CancerTYPE ID is a standardized, objective molecular test based on the differential expression of 92 genes, that classifies tumors by matching the gene expression pattern of a patientís tumor tissue to a database of known tumor types and histological subtypes.

CancerTYPE IDís database includes 2,206 tumors from multiple tumor banks, selected to provide broader and deeper representation of the heterogeneity of tumors. The 92-gene assay does not overlap with IHC markers, providing complementary data to standard tumor diagnosis.

CancerTYPE ID uses real-time reverse transcription polymerase chain reaction (RT-PCR). A very low copy number of RNA molecules can be detected, thus reducing the sample tissue required for testing. Testing is conducted and results are generated at bioTheranostics' CAP-accredited, CLIA-certified laboratory.

For more information, click here.

Advertisement


Website news:

(1) Thanks to all who stopped by our booth at CAP '11. These are the projects we are working on: (a) finish the Home Page Topic search by October 31, 2011; (b) more frequent reviews / updates of topics (ongoing); (c) new format for viewing website on iPad or Smartphones (starting to plan); (d) possibly more interesting social media discussions. Let us know what you think.

(2) Thanks to Dr. Perry Cohen, Montefiore Medical Center of the Albert Einstein College of Medicine, for his suggestion to post Cases of the Week by Category without a diagnosis, which has now been done.

(3) We posted an article on our Management Page, How to Gain a Better Managed Care Contract for your Independent Laboratory, by Mick Raich, Vachette Pathology, click here.

Case of the Week #217

Clinical History:

A 55 year old woman had a two month history of a fungating axillary tail mass, which was fixed to the skin. At excision, it was 14 x 13 cm.

Micro images:

           

What is your diagnosis?































Diagnosis:

Primary diffuse large B cell lymphoma with clear cell change

Discussion:

Immunostains were negative for cytokeratin (left) and positive for CD20 (right):

   

Primary and secondary breast lymphoma are rare, each representing less than 1% of all breast malignancies. The criteria for primary breast lymphoma are: (a) sufficient tissue for diagnosis; (b) close interaction between the lymphoma infiltrate and breast tissue; (c) no evidence of widespread lymphoma at time of diagnosis; and (d) no prior diagnosis of nonbreast lymphoma (Cancer 1972;29:1705).

Diffuse large B cell lymphoma is the most common subtype of primary breast lymphoma (Am J Hematol 2009;84:133). Clear cell change has been frequently described in mediastinal diffuse large B cell lymphomas (Blood 1987;69:1087, Virchows Arch A Pathol Anat Histopathol 1986;409:79), but not in the breast. Clear cell lymphomas have diffuse sheets and groups of malignant cells with clear vacuolated cytoplasm. The nuclei are pleomorphic, indented and vesicular. There often is necrosis and a high mitotic count.

Other primary breast tumors with clear cell changes include glycogen-rich carcinoma and some myoepithelial carcinomas. Metastatic tumors that should be considered in the differential diagnosis include perivascular epithelioid cell tumors and clear cell carcinomas from the kidney, ovary and lung.

Treatment consists of radiation therapy, chemotherapy and Rituximab (anti-CD20 antibody). Tumors with a non germinal center phenotype are more common, and genotype appears to not influence prognosis (Am J Clin Oncol 2011 Feb 15 [Epub ahead of print], but see Leuk Res 2008;32:1837).

Additional references: Breast malignant chapter-lymphoma

Nat Pernick, M.D., President
PathologyOutlines.com, Inc.
30100 Telegraph Road, Suite 408
Bingham Farms, Michigan (USA) 48025
Telephone: 248/646-0325
Email: NatPernick@Hotmail.com
Alternate email: NatPernick@gmail.com